Designation of Migalastat Hydrochloride (Galafold) as an orphan drug - ERA Consulting Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate therapeutic goods to ensure they are safe, of high quality and effective for their intended use. The Act was introduced to address the need for a comprehensive framework governing the manufacturing, advertising, supply, and importation of therapeutic goods within Australia. One notable mechanism within the Act is the designation of orphan drugs, designed to encourage the development of treatments for rare diseases that might otherwise lack sufficient incentive for pharmaceutical companies to pursue. On 2 February 2016, Dr Anthony Gill, as the Delegate of the Secretary, designated Migalastat hydrochloride (GALAFOLD) as an orphan drug under the authority provided by the Therapeutic Goods Regulations 1990. This designation was made for the long-term treatment of adult and adolescent patients with Fabry disease, a rare genetic disorder caused by a deficiency in the enzyme α-galactosidase A. The designation underscores the policy objective of providing access to potentially life-saving treatments for patients suffering from rare conditions.

Scope and Application

The Therapeutic Goods Act 1989, as amended and governed by the Therapeutic Goods Administration (TGA), designates Migalastat hydrochloride (GALAFOLD) as an orphan drug for the long-term treatment of Fabry disease in adult and adolescent patients with a confirmed diagnosis of α-galactosidase A deficiency who possess an amendable mutation. This legislation applies to the pharmaceutical product Migalastat hydrochloride, specifically for its use in treating Fabry disease, a rare genetic disorder. The designation under the Act allows for special consideration and regulatory support for the development and availability of orphan drugs which are intended for the treatment of rare diseases or conditions that affect a small population. This Act operates on a national level across the Commonwealth of Australia, providing a unified regulatory framework for therapeutic goods, including medicines, medical devices, and other related items. The scope of the Act encompasses entities involved in the research, development, manufacture, and distribution of therapeutic goods, ensuring they meet the necessary safety, quality, and efficacy standards. The Act does not explicitly state exclusions or thresholds but implies that the benefits of orphan drug designation are reserved for treatments of rare diseases, as defined by the TGA, thereby restricting its application to such contexts.

Key Provisions

The primary operative section in this legislation is the designation of Migalastat hydrochloride (GALAFOLD) as an orphan drug under the Therapeutic Goods Act 1989. Specifically, Section 16J of the Therapeutic Goods Regulations 1990 allows for the designation of certain drugs as orphan drugs, and in this instance, Migalastat hydrochloride (GALAFOLD) has been designated for the long-term treatment of patients with Fabry disease who have an amendable mutation (subsection 16J(2)). This designation acknowledges the rarity of the condition and the need for specific therapeutic agents. The designation took effect on 2 February 2016, as signed by Dr Anthony Gill, the Delegate of the Secretary. This Act imposes several obligations on the parties involved, particularly the sponsor of the drug, ERA Consulting Australia Pty Ltd. The sponsor must ensure that the therapeutic goods comply with all relevant legislative requirements and that they are safe and of high quality for their intended use. Additionally, the sponsor must provide all necessary information to the Therapeutic Goods Administration (TGA) to support the orphan drug designation and to maintain the ongoing compliance of the drug within the regulatory framework. Failure to comply with the provisions of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in significant consequences. Offences under this Act can lead to both civil and criminal penalties. For example, knowingly supplying therapeutic goods that do not comply with the standards set out in the Act can result in civil penalties, including fines of up to $222,200 for individuals and $1,111,000 for bodies corporate, as stipulated in the Act. Additionally, criminal penalties can apply, with potential imprisonment terms depending on the severity of the offence. For instance, supplying goods that cause serious harm can lead to imprisonment for up to five years. These stringent measures underscore the importance of adherence to the legislative requirements governing therapeutic goods in Australia.